Research.Patient.info
dedifferentiated liposarcoma research hub
2 indexed studies · 1 currently recruiting
- ongoing, recruitingTherapeutic confirmatory (Phase III)
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma
This study, called Brightline-4, is looking at a new drug, BI 907828, for advanced dedifferentiated liposarcoma. It aims to see how safe and effective the drug is for patients who haven't had treatment before or have had some treatment already. It's an important step to understand this new medicine.
Belgium · Italy - recruitingPHASE1
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
This study is testing a new drug, OKN4395, alone and with an existing cancer treatment, pembrolizumab, for various solid tumours. The main goals are to check its safety, how well it's tolerated, and if it helps fight cancer.
United States · Australia · United Kingdom